Fluidigm Corporation (FLDM)
-NasdaqGS | Prev Close: | 22.02 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 21.86 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 13.43 - 23.39 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 162,083 |
|---|
| Market Cap: | 561.42M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Fluidigm and NanoString (NSTG) agree to litigation settlement; NSTG to remove all references to a single-cell comparison study comparing Fluidigm and NanoStringBriefing.com(Tue, Oct 1)
- NanoString Technologies, Inc. and Fluidigm Corporation Settle LawsuitsGlobeNewswire(Tue, Oct 1)
- Fluidigm and NanoString Agree to Litigation SettlementBusiness Wire(Tue, Oct 1)
- Fluidigm C1 Single-Cell Auto Prep System Wins Prestigious IBO Design AwardBusiness Wire(Mon, Sep 9)
- Interview with William Quirk, Managing Director and Senior Research Analyst at Piper Jaffray & Co.: Solid Fundamentals for Diagnostics and Life Science Tools Despite Short-Term ChallengesWall Street Transcript(Wed, Aug 21)
- FLUIDIGM CORP FinancialsEDGAR Online Financials(Thu, Aug 15)
- Meet The Venture Arm Of The CIAat Forbes(Wed, Aug 14)
- FLUIDIGM CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 7)
- 5 Tech Stocks Rising on Big Volumeat TheStreet(Mon, Aug 5)
- Why Fluidigm Shares Flewat Motley Fool(Fri, Aug 2)
- Fluidigm Reports Strong Q2 2013 Revenue Growth of 35%Business Wire(Thu, Aug 1)
- FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, Aug 1)
- Fluidigm Enables the Study of miRNA Master Regulators Down to the Single Cell LevelBusiness Wire(Thu, Aug 1)
- Q2 2013 Fluidigm Corp Earnings Release - After Market CloseCCBN(Thu, Aug 1)
- Fluidigm and Olink Bioscience Bring a New Level of Protein Biomarker Discovery to the Life Science Research MarketBusiness Wire(Wed, Jul 31)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| FLDM | 0.00% | 561.42M |
| JDG.L | 1.32% | 89.28M |
| GRMN | 0.00% | 9.05B |
| TRMB | 0.00% | 7.89B |
| ST | 0.00% | 6.69B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.65 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | -1.40 |
|---|
Business Summary
Fluidigm Corporation develops, manufactures, and markets microfluidic systems for academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology and Ag-Bio companies.
View More